go-v.orgdoi

Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell

Chaoqun Huang, Xiaoqiong Tang, Suhuan Li, Qingshui Wang, Bifeng Xie, Jing Xu, Yao Lin · Journal of Cancer · 2019

  • DOI 10.7150/jca.29672
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2019

Abstract

Tumors can escape immunosurveillance through immunocheckpoint such as the PD-1/PD-L1 pathway.Aikejia comes from Nocardia rubra cell-wall skeleton and can increase the number of inflammatory factors and immune cells.In this work, we showed that the levels of PD-L1 increase in CT26.WT xenograft after subcutaneous injection of Aikejia in mice, but Aikejia did not induce the expression of PD-L1 in vitro.When we treated the mice with Aikejia and blocked PD-1/PD-L1 pathway in vivo at the same time, the CT26.WT xenografts were significantly inhibited or eliminated, which was better than single treatment alone.Our results suggested that Aikejia may be an effective adjuvant for PD-1/PD-L1 immunotherapy.

Open the resolved locator · 10.7150/jca.29672

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:10 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v10p3472.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.